Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck Acquires Ariad Cancer Drug
by Michael McCoy
May 10, 2010
| A version of this story appeared in
Volume 88, Issue 19
Merck & Co. has acquired development and worldwide commercialization rights for ridaforolimus, an Ariad Pharmaceuticals drug now in Phase III trials as a treatment for metastatic soft-tissue and bone cancers. Merck will pay Ariad $50 million up front and up to $514 million in milestone payments. The two firms started collaborating on the drug, a small-molecule inhibitor of the cell proliferation protein mTOR, in July 2007. Ariad says the deal will allow it to devote resources to two other cancer therapies in its pipeline.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter